Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-003084-21
    Sponsor's Protocol Code Number:cHL-PG01
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-06-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-003084-21
    A.3Full title of the trial
    A phase-II academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or nivolumab in relapsed or refractory classical Hodgkin lymphoma (cHL)
    STUDIO ACCADEMICO DI FASE-II TESTANTE, IN DUE COORTI PARALLELE NON RANDOMIZZATE, LA COMBINAZIONE DI RUXOLITINIB (INIBITORE DI JAK 1/2) CON BRENTUXIMAB-VEDOTIN O NIVOLUMAB NEL LINFOMA DI HODGKIN CLASSICO RECIDIVANTE O REFRATTARIO (cHL)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A phase-II academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or nivolumab in relapsed or refractory classical Hodgkin lymphoma (cHL)
    STUDIO ACCADEMICO DI FASE-II TESTANTE, IN DUE COORTI PARALLELE NON RANDOMIZZATE, LA COMBINAZIONE DI RUXOLITINIB (INIBITORE DI JAK 1/2) CON BRENTUXIMAB-VEDOTIN O NIVOLUMAB NEL LINFOMA DI HODGKIN CLASSICO RECIDIVANTE O REFRATTARIO (cHL)
    A.3.2Name or abbreviated title of the trial where available
    cHL-PG01
    cHL-PG01
    A.4.1Sponsor's protocol code numbercHL-PG01
    A.5.4Other Identifiers
    Name:NANumber:NA
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportFondi del Dipartimento Medicina
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationDip. di Medicina Università di Perugia
    B.5.2Functional name of contact pointSez. di Ematologia ed Immunologia C
    B.5.3 Address:
    B.5.3.1Street AddressPiazzale Menghini
    B.5.3.2Town/ cityS. Andrea delle Fratte - Perugia
    B.5.3.3Post code06132
    B.5.3.4CountryItaly
    B.5.4Telephone number0755783294
    B.5.5Fax number0623318773
    B.5.6E-mailenrico.tiacci@unipg.it
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name JAKAVI - 20 MG - COMPRESSA - USO ORALE - BLISTER (PVC/PCTFE/ALU) - 56 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderNOVARTIS EUROPHARM LTD
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRuxolitinib
    D.3.2Product code [L01XE18]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRUXOLITINIB
    D.3.9.1CAS number 941678-49-5
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeSUB32273
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ADCETRIS - 50 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO
    D.2.1.1.2Name of the Marketing Authorisation holderTAKEDA GLOBAL RESEARCH AND DEVELOPMENT CENTRE (EUROPE) LTD
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/08/596
    D.3 Description of the IMP
    D.3.1Product namebrentuximab vedotin
    D.3.2Product code [L01XC12]
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBRENTUXIMAB VEDOTIN
    D.3.9.1CAS number 211323-03-4
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeSUB32397
    D.3.10 Strength
    D.3.10.1Concentration unit µg/kg microgram(s)/kilogram
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number18000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name KEYTRUDA - 50 MG- POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO) 1 FLACONCINO
    D.2.1.1.2Name of the Marketing Authorisation holderMERCK SHARP & DOHME LIMITED
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePembrolizumab
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNpembrolizumab
    D.3.9.1CAS number 1374853-91-4
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeSUB167136
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with relapsed or refractory cHL that has not responded to, or has progressed after, the previous treatment
    Pazienti con Linfoma di Hodgkin (cHL) recidivato o refrattario che non abbiano risposto o siano andati in progressione dopo il precedente trattamento
    E.1.1.1Medical condition in easily understood language
    Patients with relapsed or refractory cHL that has not responded to, or has progressed after, the previous treatment
    Pazienti con Linfoma di Hodgkin (cHL) recidivato o refrattario che non abbiano risposto o siano andati in progressione dopo il precedente trattamento
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10020328
    E.1.2Term Hodgkin's lymphoma
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine, in patients with relapsed or refractory cHL, the rate of complete response (CR) to ruxolitinib in combination with brentuximab (Cohort-1) or nivolumab (Cohort-2), reached by the end of treatment with the study drug combination.
    Determinare il tasso di risposta completa (CR) raggiunto al termine del trattamento di combinazione con ruxolitinib e brentuximab (Coorte-1) o nivolumab (Coorte-2) in pazienti affetti da cHL recidivato/refrattario
    E.2.2Secondary objectives of the trial
    • To assess the safety of ruxolitinib in combination with brentuximab (Cohort-1) or nivolumab (Cohort-2).
    • To determine the rates of partial response (PR) and stable disease (SD) observed during ruxolitinib treatment and/or at the end of ruxolitinib treatment.
    • To determine the rate of CR, PR and SD observed while patients are off-ruxolitinib and may continue brentuximab (Cohort-1) or nivolumab (Cohort-2) on study.
    • To assess the rate of successful hematopoietic stem cell harvesting and bridging to transplantation in both cohorts.
    • To assess the efficacy of subsequent treatments that the patients might receive after those planned in the current study.
    • To assess the survival of patients.
    • To identify genetic and non-genetic biomarkers of response through centralized analysis (at the Sponsor Institution) of solid and serial liquid biopsies.
    • Valutare la sicurezza del ruxolitinib utilizzato in combinazione con brentuximab (coorte-1) o nivolumab (coorte-2).
    • Determinare i tassi di risposta parziale (PR) e malattia stabile (SD) osservati durante il trattamento con ruxolitinib e al termine dello stesso.
    • Determinare i tassi di CR, PR e SD osservati dopo il termine della terapia con ruxolitinib nei pazienti che continuano il brentuximab (Coorte-1) o il nivolumab (Coorte-2) all’interno dello studio.
    • Valutare il tasso di riuscita nella raccolta di cellule staminali e “bridging” al trapianto in entrambe le coorti.
    • Valutare l’efficacia di trattamenti successivi che il paziente potrà ricevere dopo quelli previsti dallo studio.
    • Determinare la durata di risposta e la sopravvivenza dei pazienti.
    • Identificare biomarcatori di risposta genetici e non-genetici attraverso un’analisi centralizzata (presso il centro coordinatore) di campioni bioptici tissutali e biopsie liquide seriate.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Cohort-1: ruxolitinib + brentuximab
    1. Adult patients with CD30+ cHL relapsed or refractory after autologous stem cell transplantation (ASCT), or after at least two previous lines of treatment if ASCT or polichemotherapy do not represent treatment options (as per AIFA label of brentuximab). Patients must also fulfill other specific inclusion and exclusion criteria described below ("Additional inclusion and exclusion criteria").
    [2.Even when fulfilling the criteria of point 1 above, patients cannot be enrolled if:
    i) They had previously received an allotransplant (as they would be blocked by the AIFA registry for brentuximab);
    ii) or they can receive less than 6 infusions of brentuximab through the AIFA registry (due to previous infusions of the drugs through the registry);
    iii) or they had progressed on brentuximab after activating the AIFA registry for this drug (because progression on brentuximab recorded in the AIFA registry would block further requests of the drug through this registry).
    3. If complying with the criteria of points 1 and 2 above, patients progressing after previous treatment in Cohort-2 may be enrolled in Cohort-1 upon decision of the Sponsor in conjunction with the clinical investigator(s).
    4. If complying with the criteria of points 1 and 2 above, patients taken off Cohort-2 due to important toxicity from nivolumab may be enrolled in Cohort-1, upon decision of the Sponsor in conjunction with the clinical investigator(s), as long as they have not responded (i.e., no PR nor CR) to the treatment received in Cohort-2.

    Cohort 2: ruxolitinib + nivolumab
    1. Adult patients with relapsed or refractory cHL previously treated with both ASCT and brentuximab (as per AIFA label of nivolumab). Patients must also fulfill other specific inclusion and exclusion criteria described below (see below section "Additional inclusion and exclusion criteria").
    2. Patients fulfilling the criteria of point 1 above can be enrolled even if:
    i) They had previously received an allotransplant (which does not block the AIFA registry for nivolumab);
    ii) They had progressed on nivolumab before activating the AIFA registry for this drug (as they might benefit from combining ruxolitinib to nivolumab). However, even if fulfilling the criteria of point 1 above, patients cannot be enrolled if they progressed on nivolumab after activating the AIFA registry for this drug (because progression on nivolumab recorded in the AIFA registry would block further requests of the drug through this registry).
    3. If complying with the criteria of points 1 and 2 above, patients progressing after previous treatment in Cohort-1 may be enrolled in Cohort-2 upon decision of the Sponsor in conjunction with the clinical investigator(s).
    4. If complying with the criteria of points 1 and 2 above, patients taken off Cohort-1 due to important toxicity from brentuximab may be enrolled in Cohort-2, upon decision of the Sponsor in conjunction with the clinical investigator(s), as long as they have not responded (i.e., no PR nor CR) to the treatment received in Cohort-1.
    Additional inclusion criteria (for both cohorts, see the specific section of the protocol)
    Coorte-1: ruxolitinib + brentuximab
    1. Pazienti adulti con cHL CD30+ recidivato o refrattario dopo trapianto autologo di cellule staminali emopoietiche (ASCT), o dopo almeno due precedenti linee di terapia se l’ASCT o la polichemioterapia non rappresentano opzioni di trattamento (come previsto da indicazione AIFA per brentuximab). I pazienti dovranno inoltre soddisfare ulteriori criteri specifici di inclusione ed esclusione descritti sotto (si veda la sezione "criteri di inclusione ed esclusione addizionali").
    [2.Anche in caso soddisfino il criterio di cui sopra al punto 1, i pazienti non potranno essere arruolati nel caso che:
    i)abbiano ricevuto in precedenza un trapianto allogenico (in quanto questa fattispecie è bloccata dal registro AIFA del brentuxuimab);
    ii)possano ricevere meno di 6 infusioni di brentuximab mediante il registro AIFA (a causa del numero di infusioni già registrate);
    iii)siano andati incontro a progressione di malattia durante il trattamento con brentuximab dopo aver attivato il registro AIFA per tale farmaco (in quanto una progressione sotto brentuximab inserita nel registro AIFA bloccherebbe ulteriori richieste di farmaco attraverso il registro stesso). Tuttavia pazienti che soddisfino il criterio 1 potranno essere arruolati anche in caso di progressione in corso di brentuximab se questa è avvenuta prima dell’attivazione del registro AIFA (in quanto in questo caso non sarebbe stata registrata la progressione e i pazienti potrebbero beneficiare della terapia di combinazione con ruxolitinib e brentuximab).]
    3. In caso soddisfino i criteri ai punti 1 e 2 di cui sopra, i pazienti in progressione dopo un precedente trattamento in Coorte-2 potranno essere arruolati in Coorte-1 previa decisione congiunta del Promotore e dello sperimentatore(i).
    4. In caso soddisfino i criteri ai punti 1 e 2 di cui sopra, i pazienti usciti dalla Coorte-2 a causa di tossicità importante da nivolumab potranno essere arruolati nella Coorte-1, previa decisione congiunta del Promotore e dello sperimentatore(i), in caso di mancata risposta (no PR, no CR) al trattamento ricevuto all’interno della Coorte-2.
    Coorte-2: ruxolitinib + nivolumab
    1. Pazienti adulti con cHL recidivato o refrattario già trattati in precedenza sia con ASCT che con brentuximab (come previsto da indicazione AIFA per nivolumab). I pazienti dovranno inoltre soddisfare ulteriori criteri specifici di inclusione ed esclusione descritti sotto (si veda la sezione "criteri di inclusione ed esclusione addizionali").
    2. I pazienti che soddisfano il criterio di cui sopra al punto 1, potranno essere arruolati anche nel caso che:
    i) abbiano ricevuto in precedenza un trapianto allogenico (che non blocca il registro AIFA del nivolumab);
    ii) siano andati in progressione in corso di trattamento con nivolumab prima di attivare il registro AIFA per questo farmaco (in quanto potrebbero beneficiare della terapia di combinazione con ruxolitinib e nivolumab).
    3. in caso soddisfino i criteri ai punti 1 e 2 di cui sopra, i pazienti in progressione dopo un precedente trattamento in Coorte-1 potranno essere arruolati in Coorte-2 previa decisione congiunta del Promotore e dello sperimentatore(i).
    4. in caso soddisfino i criteri ai punti 1 e 2 di cui sopra, i pazienti usciti dalla Coorte-1 a causa di tossicità importante da brentuximab potranno essere arruolati nella Coorte-2, previa decisione congiunta del Promotore e dello sperimentatore(i), in caso di mancata risposta (no PR, no CR) al trattamento ricevuto all’interno della Coorte-1.
    Criteri di inclusione addizionali (per entrambi le coorti vedere sezione specifica protocollo).
    E.4Principal exclusion criteria
    Cohort-1: ruxolitinib + brentuximab
    2. Patients cannot be enrolled if:
    i) They had previously received an allotransplant (as they would be blocked by the AIFA registry for brentuximab);
    ii) or they can receive less than 6 infusions of brentuximab through the AIFA registry (due to previous infusions of the drugs through the registry);
    iii) or they had progressed on brentuximab after activating the AIFA registry for this drug (because progression on brentuximab recorded in the AIFA registry would block further requests of the drug through this registry). However, patients fulfilling the criteria of point 1 above can be enrolled if they progressed on brentuximab before activating the AIFA registry (as no record of progression would be present in this registry and the patients might benefit from combining ruxolitinib to brentuximab).
    Cohort-2: ruxolitinib + nivolumab
    2. ii) Patients cannot be enrolled if they progressed on nivolumab after activating the AIFA registry for this drug (because progression on nivolumab recorded in the AIFA registry would block further requests of the drug through this registry).

    Additional exclusion criteria (for both cohorts, except where noted):
    1. Previous treatment of cHL with ruxolitinib or another JAK inhibitor received before enrollment in the trial
    2. Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption. Patients must be able to swallow capsules.
    3. CNS involvement by lymphoma
    4. Currently uncontrolled active infection
    5. Other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may, in the judgment of the clinical investigator and/or the Sponsor, increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or may make the patient inappropriate for entry into this study
    6. Pregnant or lactating females, or patients who are not willing to use an adequate method of birth control until 6 month after the last dose of brentuximab or nivolumab
    7. Inability to comply with other requirements of the protocol
    8. [for Cohort-2 only] Symptomatic interstitial lung disease or active autoimmune disease (except for vitiligo, type-1 diabetes, hypothyroidism secondary to autoimmune thyroiditis requiring hormonal replacement therapy, and psoriasis not requiring systemic treatment), as per AIFA registry of nivolumab
    9. [for Cohort-2 only] Therapy with systemic immunosuppressive agents (which would be blocked by the AIFA registry of nivolumab, except for doses = 10 mg/day of prednisone or equivalent corticosteroids) must have been stopped since at least 2 weeks
    Coorte-1: ruxolitinib + brentuximab
    2. I pazienti non potranno essere arruolati nel caso che:
    i) abbiano ricevuto in precedenza un trapianto allogenico (in quanto questa fatti specie è bloccata dal registro AIFA del brentuxuimab);
    ii) possano ricevere meno di 6 infusioni di brentuximab mediante il registro AIFA (a causa del numero di infusioni già registrate);
    iii) siano andati incontro a progressione di malattia durante il trattamento con brentuximab dopo aver attivato il registro AIFA per tale farmaco (in quanto una progressione sotto brentuximab inserita nel registro AIFA bloccherebbe ulteriori richieste di farmaco attraverso il registro stesso). Tuttavia pazienti che soddisfino il criterio 1 potranno essere arruolati anche in caso di progressione in corso di brentuximab se questa è avvenuta prima dell’attivazione del registro AIFA (in quanto in questo caso non sarebbe stata registrata la progressione e i pazienti potrebbero beneficiare della terapia di combinazione con ruxolitinib e brentuximab).

    Coorte-2: ruxolitinib + nivolumab
    2. ii) I pazienti non potranno essere arruolati in caso di progressione sotto nivolumab avvenuta dopo l’attivazione del registro AIFA per il farmaco (in quanto una progressione sotto nivolumab inserita nel registro AIFA bloccherebbe ulteriori richieste di farmaco attraverso il registro stesso).

    Criteri di esclusione addizionali (per entrambe le coorti, eccetto dove diversamente contrassegnato):
    1. Precedente trattamento del cHL con ruxolitinib o un altro inibitore di JAK prima dell’arruolamento nello studio.
    2. Nausea e vomito refrattari, malassorbimento, shunt biliare esterno o significativa resezione intestinale che possano precludere l’adeguato assorbimento intestinale. I pazienti devono essere in grado di deglutire le capsule.
    3. Localizzazione linfomatosa al sistema nervoso centrale.
    4. Presenza di infezione attiva e non controllata.
    5. Altre condizioni mediche o psichiatriche acute o croniche severe o anomalie di laboratorio che possano, a giudizio dello sperimentatore(i) e/o del Promotore, incrementare i rischi associati con la partecipazione allo studio o con la somministrazione dei farmaci in studio, possano interferire con l’interpretazione dei risultati dello studio, o possano rendere il paziente non idoneo per l’arruolamento in questo protocollo.
    6. Donne in gravidanza o durante l’allattamento, o pazienti che non vogliano utilizzare metodi adeguati di contraccezione durante il trattamento e per 6 mesi dopo l’ultima dose di brentuximab o nivolumab.
    7. Incapacità di ottemperare ad altri requisiti del protocollo.
    8. [solo per la Coorte-2] malattia interstiziale polmonare sintomatica o malattia autoimmune attiva (con l’eccezione di vitiligine, diabete di tipo-1, ipotiroidismo secondario a tiroidite autoimmune che richieda terapia ormonale sostitutiva e psoriasi tale da non richiedere trattamento sistemico), come previsto dal registro AIFA del nivolumab.
    9. [solo per la Coorte-2] il trattamento con immunosoppressori sistemici (che bloccherebbe il registro AIFA del nivolumab, eccetto per dosi = 10 mg/die e di prednisone o equivalenti corticosteroidi) deve essere stato sospeso da almeno due settimane.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint in each cohort is to meet or exceed, according to a per-protocol analysis, a pre-determined rate of CR by the end of treatment with the study drug combination (i.e., obtained either at the interim disease evaluation during treatment or at the end of treatment with the study drug combination). The rate of CR has been set at =40% in Cohort-1 and =30% in Cohort-2 (see also "Statistical design and safety measures" below) to improve on the historical CR rates, in relapsed/refractory cHL, of monotherapy with brentuximab (~15-30% depending on the study population) and nivolumab (~10-20%, depending on the study population). The rate of CR will be also assessed according to an intention-to-treat analysis for informative purpose only, because this is a phase-2 non-randomized trial primarily designed to test the anti-lymphoma activity of the study drug combinations.
    L’endpoint primario in ogni corte è quello di raggiungere o superare, secondo le metodiche di analisi previste dal protocollo, un tasso predeterminato di CR entro la fine del trattamento di combinazione (cioè ottenuto alla rivalutazione di malattia ad interim durante il trattamento di combinazione o alla fine del trattamento di combinazione stesso). I tassi di CR prestabiliti sono =40% per la Coorte-1 e =30% per la Coorte-2 (si veda anche la sezione "disegno statistico e misure di sicurezza" di seguito) al fine di migliorare i tassi di storici di CR, nel cHL recidivato refrattario, della monoterapia con brentuximab (~15-30% in base alla popolazione in studio) e nivolumab (~10-20%, in base alla popolazione in studio). Il tasso di CR sarà anche valutato mediante analisi “intention-to-treat” a solo scopo informativo, in quanto questo è un protocollo di fase-2 non-randomizzato disegnato per testare l’attività anti-linfomatosa della combinazione di farmaci in studio.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The timepoints of primary end point evaluation for both treatment cohorts will be after 9 weeks and after 18 weeks of treatment with the study drug combination.
    I Tempi di rilevazione dell'end point primario per entrambe le coorti di trattamento sono dopo 9 settimane e dopo 18 settimane di trattamento con la combinazione dei due farmaci.
    E.5.2Secondary end point(s)
    1. To describe the type, incidence, grade and relationship to the study drugs of adverse events (AE) occurring in each cohort.
    2. To determine the rates of partial response (PR) and stable disease (SD) observed during ruxolitinib treatment and/or at the end of ruxolitinib treatment.
    3. To determine the rate of CR, PR and SD observed while patients are off-ruxolitinib and may continue brentuximab (Cohort-1) or nivolumab (Cohort-2) on study.
    4. To assess the rate of successful hematopoietic stem cell harvesting and bridging to transplantation in both cohorts.
    5. To assess the specific type, efficacy and toxicity of subsequent treatments that the patients might receive after those planned in the current study.
    6. To assess the survival of patients:
    • Progression-free survival, i.e. from start of treatment until date of
    progression;
    • Overall survival, i.e. from start of treatment until death from any cause;
    • Disease-specific survival, i.e. from start of treatment until death due to the disease or to its treatment;
    • Treatment-free survival, i.e. from the end of study treatment until the beginning of a new treatment other than those planned in this study.
    7. To identify potential biomarkers of response through centralized analysis (at the Sponsor institution) of:
    • Genetic and protein studies on archival and/or newly performed biopsies (e.g., genetic lesions of JAK-STAT pathway members; expression of PDL1, MHC-II, MHC-I and phosphorylated STAT transcription factors)
    • Genetic and chemokine (e.g., TARC) studies on liquid biopsies taken before, during and after the study treatments.
    1. Descrivere la tipologia, l’incidenza, il grado e la relazione causale con I farmaci in studio degli eventi avversi (AE) occorsi in ciascuna coorte.
    2. Determinare i tassi di risposta parziale (PR) e malattia stabile (SD) osservati durante il trattamento con ruxolitinib e/o alla fine del trattamento con ruxolitinib.
    3. Determinare il tasso di CR, PR e SD osservato nei pazienti che, una volta terminato il ruxolitinib continuano il brentuximab (Coorte-1) o il nivolumab (Coorte-2) all’interno dello studio.
    4. Valutare il tasso di riuscita nella raccolta di cellule staminali e “bridging” al trapianto in entrambe le coorti.
    5. Valutare il tipo specifico, l’efficacia e la tossicità di trattamenti successivi che il paziente potrà ricevere dopo quelli previsti dallo studio
    6. Valutare la sopravvivenza dei pazienti:
    • “Progression-free survival”, misurata dall’inizio del trattamento fino alla data della progressione;
    • “Overall survival”, misurata dall’inizio del trattamento fino alla morte per qualsiasi causa;
    • “Disease-specific survival”, misurata dall’inizio del trattamento fino a morte dovuta alla malattia o al suo trattamento;
    • “Treatment-free survival”, misurata dalla fine del trattamento previsto dallo studio fino all’inizio di un nuovo trattamento al di fuori di quelli pianificati in questo studio.
    7. Identificare potenziali biomarcatori di risposta mediante analisi centralizzata (presso il centro coordinatore) di:
    • Studi genetici e di proteine su biopsie da archivio o di nuova esecuzione (ad es. Lesioni genetiche dei membri della via di JAK-STAT; espressione di PDL1, MHC-II, MHC-I e fattori di trascrizione STAT fosforilati)
    • Studi genetici e di chemochine (es. TARC) su biopsie liquid prelevate prima, durante e dopo il trattamento previsto dallo studio.
    E.5.2.1Timepoint(s) of evaluation of this end point
    The timepoints of secondary end points' evaluation for both treatment cohorts will be during the 3-year follow-up after the end of treatment with the study drug combination.
    I tempi di rilevazione degli end points secondari per entrambe le coorti di trattamento saranno durante i 3 anni di follow-up dopo la fine del trattamento di combinazione.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over Yes
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    COMBINAZIONE DI FARMACI IN DUE COORTI PARALLELE NON RANDOMIZZATE
    COMBINATION OF DRUGS IN TWO PARALLEL, NON-RANDOMIZED COHORTS
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months60
    E.8.9.1In the Member State concerned days18
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months60
    E.8.9.2In all countries concerned by the trial days18
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 19
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 8
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state27
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 27
    F.4.2.2In the whole clinical trial 27
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    STANDARD CARE
    NORMALE PRATICA CLINICA
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-01-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-09-26
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 09:01:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA